Vaccination in immunocompromised populations is challenging due to the increased risk of adverse effects and reduced immune response. Immunocompromised individuals, such as organ transplant recipients, cancer patients undergoing chemotherapy, and people with autoimmune diseases, often cannot tolerate live-attenuated vaccines. Instead, they require safer, inactivated, or subunit vaccines to avoid potential health risks. Specialized vaccine formulations are being developed to provide effective immune protection while minimizing risks for these populations. Additionally, healthcare providers may adopt a more individualized vaccination approach, considering each patient’s specific health condition and immune status. Enhancing vaccine efficacy and safety for immunocompromised individuals is crucial, as they are at higher risk for severe disease outcomes. This research addresses an essential healthcare need, allowing these vulnerable populations to receive effective immunity without compromising their health.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States